Reduced ability to neutralize the Omicron variant among adults after infection and complete vaccination with BNT162b2, ChAdOx1, or CoronaVac and heterologous boosting.

Espíndola, Otávio Melo; Fuller, Trevon L; de Araújo, Mia Ferreira; Tort, Luis Fernando Lopez; Guaraldo, Lusiele; Calvet, Guilherme; Resende, Paola; Bonaldo, Myrna; Whitworth, Jimmy; Smith, Chris; +2 more... Siqueira, Marilda; Brasil, Patrícia; (2023) Reduced ability to neutralize the Omicron variant among adults after infection and complete vaccination with BNT162b2, ChAdOx1, or CoronaVac and heterologous boosting. Scientific Reports, 13 (1). 7437-. ISSN 2045-2322 DOI: https://doi.org/10.1038/s41598-023-34035-9

Abstract

COVID-19 vaccines have dramatically reduced rates of severe infection requiring hospitalization. However, SARS-CoV-2 variants have reduced vaccine effectiveness at preventing any symptomatic infection. This real-world study analyzed binding and neutralizing antibodies generated after complete vaccination and boosting across three vaccine platforms. Binding antibodies decayed most slowly in people under 60 with hybrid immunity. Neutralizing antibodies against Omicron BA.1 were reduced compared to other variants. The anamnestic anti-spike IgG response to the first boost was more pronounced than after the second boost. Monitoring of the effects of SARS-CoV-2 mutations on disease severity and the effectiveness of therapeutics is warranted.

Additional Information

Item Type	Article
Faculty and Department	Faculty of Epidemiology and Population Health > Dept of Infectious Disease Epidemiology (-2023) Faculty of Infectious and Tropical Diseases > Dept of Clinical Research
Research Centre	Covid-19 Research
PubMed ID	37156846
Elements ID	202975
Official URL	http://dx.doi.org/10.1038/s41598-023-34035-9